Last updated: June 27, 2026
Taro Pharmaceuticals North America v. Suven Life Sciences, Ltd. (3:11-cv-02452): Litigation Summary, Claim Analysis, and Generic Entry Risk
What is the litigation timeline for Taro v. Suven Life Sciences, Ltd. (3:11-cv-02452)?
Case caption: Taro Pharmaceuticals North America, Inc. v. Suven Life Sciences, Ltd.
Court docket: 3:11-cv-02452 (U.S. federal court)
Core dispute type (high confidence): Patent infringement under the Hatch-Waxman framework, commonly tied to an ANDA and Orange Book-listed patents for a small-molecule drug product.
Procedural chronology (what can be stated without fabricating docket events):
- Filed: 2011 (as reflected by the “3:11-cv-02452” docket number).
- Parties: Taro Pharmaceuticals North America, Inc. (plaintiff) vs. Suven Life Sciences, Ltd. (defendant).
- Claims posture: Patent infringement litigation initiated by Taro against Suven, consistent with a Paragraph IV or related ANDA-triggered dispute pattern.
No specific dates, asserted patents, claim numbers, or procedural dispositions can be accurately provided from the docket number alone without accessing the case record.
What patents were asserted, and which claims were at issue?
A litigation “summary and analysis” requires the asserted patent identifiers (e.g., US patent numbers), specification-to-claim mapping, and claim constructions. Those elements are not derivable from the docket number and cannot be reported here without risking incorrect identification.
How do courts typically analyze infringement in ANDA patent cases like Taro v. Suven?
In Hatch-Waxman litigation, courts generally evaluate:
- Infringement of asserted claims based on the ANDA product as described in the notice of certification and related ANDA exhibits.
- Claim construction for disputed terms (often the key driver of outcome).
- Invalidity defenses such as anticipation, obviousness, lack of enablement, indefiniteness, written description, and prosecution history estoppel.
- Indefinite/means-plus-function issues when relevant to formulation or structural claims.
This analytic structure is consistent across small-molecule ANDA cases, but the specific facts, claim limitations, and results for this docket require docket-specific inputs that are not available in the prompt.
What claim-construction issues usually decide these cases?
Claim construction in ANDA disputes commonly turns on:
- Whether product parameters (e.g., particle size, polymorph, purity, solid-state form, salt form, excipient ratios) are limiting.
- Whether process parameters (e.g., manufacturing method steps) define patent scope.
- Whether method-of-use claims require a specific prescribing or dosing regimen.
Again, the presence and effect of these issues in 3:11-cv-02452 cannot be stated reliably without the claim construction order.
What was Suven’s defense strategy in this litigation?
Typical defense categories in ANDA cases:
- Non-infringement (ANDA product composition/process does not read on the asserted claim limitations).
- Invalidity (anticipation/obviousness based on prior art; written description/enablement; indefiniteness).
- Procedural defenses (jurisdictional timing, standing, or limitations tied to certification type).
This is a general framework; it is not a case-specific defense map.
What did the court decide, and what is the outcome?
A litigation outcome requires at least one of:
- A final judgment date,
- A summary judgment ruling,
- A bench trial result,
- A stipulated dismissal or settlement termination.
Those results cannot be provided from the docket number alone.
Was there a settlement or consent judgment, and what does it mean for generic entry?
A settlement in this docket would typically translate into:
- A modified launch date,
- No-Design-Around commitments,
- Confidential licensing terms,
- Forfeiture or stipulated injunctions tied to an exclusivity or patent expiration window.
Without the docket’s settlement record, any launch-date or injunction/entry analysis would be speculative.
What is the Orange Book status relevant to this dispute?
For Hatch-Waxman disputes, the relevant Orange Book facts include:
- Listed patents tied to the drug (drug-code level and strengths),
- Patent expiration dates,
- Which patents triggered the infringement notice,
- Whether each patent is “submitted,” “approved,” or “listed” with tie to a specific NDA/BLA.
None of these details are present in the prompt, and no accurate drug identification can be assumed without the case pleadings or Orange Book listing.
Which companies are impacted beyond Taro and Suven?
Patent litigation can create spillover risk for:
- Other ANDA filers at the same drug,
- Authorized generics and label-copy products,
- Licensees who design around the same formulation/method claims.
This impact analysis depends on the drug name, asserted patents, and the parties’ ANDA status, none of which are provided.
How strong is the patent estate implied by this litigation?
Patent-strength scoring requires:
- Asserted claim types (composition, polymorph, formulation, method-of-use),
- Typical validity outcomes in the same jurisdiction,
- Claim breadth and how courts construe the key limitations.
No patent numbers or claim descriptors are provided, so no strength assessment can be made.
What generic entry risks exist for Suven if the case resolved against it?
If a defendant loses, common commercial consequences include:
- An injunction preventing launch of the ANDA product until patent expiration or a successful appeal.
- Added exposure for design-around attempts if the design falls within claim scope.
If the defendant wins, entry risk drops for the particular asserted patents, though other unasserted patents and exclusivities may still block launch.
This is general ANDA logic, not a docket-specific risk conclusion.
How does this compare with other Taro vs. generic/patentee disputes?
Taro’s litigation posture in ANDA settings often focuses on:
- Broad enforcement of Orange Book-listed patents,
- Assertion of composition/formulation and/or method-of-use claims depending on the product’s patent package.
But a comparison requires:
- Drug identities,
- Specific asserted patents,
- Settlement or judgment outcomes across cases.
Without those details for this docket, no accurate comparison is possible.
Key Takeaways
- Case identity: Taro Pharmaceuticals North America, Inc. v. Suven Life Sciences, Ltd., docket 3:11-cv-02452 filed in 2011.
- What cannot be stated accurately here: asserted patent numbers, claim constructions, infringement/invalidity findings, judgment/settlement terms, and Orange Book tie-in. Those require docket-specific records not provided in the prompt.
- Business implication framework: In ANDA patent disputes, outcomes typically govern launch timing through injunctions, settlement launch dates, or invalidation. The case-specific effect cannot be quantified without the case record.
FAQs
- What patents were at issue in Taro Pharmaceuticals North America v. Suven Life Sciences (3:11-cv-02452)?
- Did the court issue claim construction orders in 3:11-cv-02452, and which terms were construed?
- Was the case resolved by final judgment, dismissal, or settlement, and what was the effective date?
- How would an adverse judgment in this docket affect ANDA launch and design-around strategy?
- Which Orange Book-listed patents likely triggered the dispute tied to this case?
References
(No sources were provided in the prompt, and no docket documents were supplied for citation.)
